Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma

• Published in: Histopathology 2008-09, Vol.53 (3), p.267-277
• Main Authors: Marquard, L, Gjerdrum, L M, Christensen, Ib J, Jensen, P B, Sehested, M, Ralfkiaer, E
• Format: Article
• Language: English
• Subjects: Acetylation; Biological and medical sciences; Cell Line, Tumor; cutaneous T-cell lymphoma; Enzyme Inhibitors - pharmacology; Histone Deacetylase 1; Histone Deacetylase 2; Histone Deacetylase 6; Histone Deacetylase Inhibitors; histone deacetylases; Histone Deacetylases - metabolism; histone H4; Histones - antagonists & inhibitors; Histones - metabolism; Humans; Immunohistochemistry; Investigative techniques, diagnostic techniques (general aspects); Lymphoma, T-Cell, Cutaneous - diagnosis; Lymphoma, T-Cell, Cutaneous - enzymology; Lymphoma, T-Cell, Cutaneous - metabolism; Medical sciences; Original; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques; Repressor Proteins - antagonists & inhibitors; Repressor Proteins - metabolism; Skin Neoplasms - diagnosis; Skin Neoplasms - enzymology; Skin Neoplasms - metabolism; survival
• ISSN: 0309-0167; 1365-2559
• DOI: 10.1111/j.1365-2559.2008.03109.x

Aims:  Aberrant histone acetylation has been associated with malignancy and histone deacetylase (HDAC) inhibitors are currently being investigated in numerous clinical trials. So far, the malignancy most sensitive to HDAC inhibitors has been cutaneous T‐cell lymphoma (CTCL). The reason for this sensitivity is unclear and studies on HDAC expression and histone acetylation in CTCL are lacking. The aim of this study was to address this issue. Methods and results:  The immunohistochemical expression of HDAC1, HDAC2, HDAC6, and acetylated H4 was examined in 73 CTCLs and the results related to histological subtypes and overall survival. HDAC1 was most abundantly expressed (P